

# Juanita Lopez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1591149/publications.pdf>

Version: 2024-02-01

56  
papers

5,929  
citations

236612

25  
h-index

174990

52  
g-index

56  
all docs

56  
docs citations

56  
times ranked

10112  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors. , 2022, 10, e004495.		14
2	Abstract CT140: ANV419, an IL-2R-beta-gamma targeted antibody-IL-2 fusion protein, induces selective effector cell proliferation in patients with progressed cancer. Cancer Research, 2022, 82, CT140-CT140.	0.4	2
3	A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours. British Journal of Cancer, 2021, 124, 391-398.	2.9	10
4	Research Related Tumour Biopsies in Early-Phase Trials with Simultaneous Molecular Characterisation â€“ a Single Unit Experience. Cancer Treatment and Research Communications, 2021, 27, 100309.	0.7	2
5	First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors. EClinicalMedicine, 2021, 34, 100797.	3.2	115
6	Quantitative Multiplex Immunofluorescence Evaluation of the Tumor Microenvironment in Pretreatment Tumors of Patients with Metastatic Breast Cancer and Serous Ovarian Carcinoma Treated with Liposomal Eribulin. Cancer Investigation, 2021, 39, 466-472.	0.6	0
7	HER3 expression and MEK activation in non-small-cell lung carcinoma. Lung Cancer Management, 2021, 10, LMT48.	1.5	7
8	Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study. Clinical Cancer Research, 2021, 27, 5213-5224.	3.2	53
9	Study protocol for a randomised controlled trial of enhanced informed consent compared to standard informed consent to improve patient understanding of early phase oncology clinical trials (CONSENT). BMJ Open, 2021, 11, e049217.	0.8	2
10	Treatment with pembrolizumab in programmed death ligand 1â€“positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTEâ€“28 trial. Cancer, 2021, 127, 1620-1629.	2.0	56
11	Preliminary evidence of antitumour activity of Ipatasertib (Ipat) and Atezolizumab (ATZ) in glioblastoma patients (pts) with PTEN loss from the Phase 1 Ice-CAP trial (NCT03673787). Neuro-Oncology, 2021, 23, iv10-iv10.	0.6	0
12	Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours. British Journal of Cancer, 2020, 123, 1360-1369.	2.9	10
13	Intermittent schedules of the oral RAFâ€“MEK inhibitor CH5126766/VX-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study. Lancet Oncology, The, 2020, 21, 1478-1488.	5.1	41
14	A risk-based approach to experimental early phase clinical trials during the COVID-19 pandemic. Lancet Oncology, The, 2020, 21, 889-891.	5.1	4
15	Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncology, The, 2020, 21, 1353-1365.	5.1	1,363
16	Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2020, 38, 3195-3204.	0.8	152
17	Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab. , 2020, 8, e000713.		8
18	Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials. Clinical Cancer Research, 2020, 26, 4805-4813.	3.2	12

#	ARTICLE	IF	CITATIONS
19	Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 7331-7339.	3.2	110
20	Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours. <i>British Journal of Cancer</i> , 2019, 120, 379-386.	2.9	16
21	Multidisciplinary interventions in a specialist Drug Development Unit to improve family history documentation and onward referral of patients with advanced cancer to cancer genetics services. <i>European Journal of Cancer</i> , 2019, 114, 97-106.	1.3	4
22	T-Cellâ€œInflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. <i>Journal of Clinical Oncology</i> , 2019, 37, 318-327.	0.8	656
23	To Cycle or Fightâ€œCDK4/6 Inhibitors at the Crossroads of Anticancer Immunity. <i>Clinical Cancer Research</i> , 2019, 25, 21-28.	3.2	46
24	Radium-223 in combination with paclitaxel in cancer patients with bone metastases: safety results from an open-label, multicenter phase Ib study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1092-1101.	3.3	13
25	Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach. <i>Clinical Medicine Insights: Oncology</i> , 2018, 12, 117955491875907.	0.6	4
26	Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience. <i>Journal of Neuro-Oncology</i> , 2018, 139, 107-116.	1.4	5
27	Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1â€œPositive Endometrial Cancer: Results From the KEYNOTE-028 Study. <i>Obstetrical and Gynecological Survey</i> , 2018, 73, 26-27.	0.2	7
28	Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit. <i>Clinical Oncology</i> , 2018, 30, 185-191.	0.6	3
29	Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors. <i>European Journal of Cancer</i> , 2018, 89, 56-63.	1.3	60
30	Combining DNA damaging therapeutics with immunotherapy: more haste, less speed. <i>British Journal of Cancer</i> , 2018, 118, 312-324.	2.9	184
31	A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials. <i>European Journal of Cancer</i> , 2018, 104, 32-38.	1.3	15
32	Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre. <i>British Journal of Cancer</i> , 2018, 119, 922-927.	2.9	3
33	Detection of circulating tumour cell clusters in human glioblastoma. <i>British Journal of Cancer</i> , 2018, 119, 487-491.	2.9	98
34	Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. <i>Annals of Oncology</i> , 2018, 29, 1807-1813.	0.6	261
35	Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials. <i>European Journal of Cancer</i> , 2018, 101, 55-61.	1.3	6
36	Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591878665.	1.4	105

#	ARTICLE	IF	CITATIONS
37	CNS cancer immunity cycle and strategies to target this for glioblastoma. <i>Oncotarget</i> , 2018, 9, 22802-22816.	0.8	11
38	Next Generation Cancer Vaccinesâ€”Make It Personal!. <i>Vaccines</i> , 2018, 6, 52.	2.1	20
39	Combine and conquer: challenges for targeted therapy combinations in early phase trials. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 57-66.	12.5	239
40	Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. <i>Lancet Oncology</i> , The, 2017, 18, 623-630.	5.1	425
41	Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials. <i>European Journal of Cancer</i> , 2017, 76, 52-59.	1.3	10
42	Emerging biomarkers for PD-1 pathway cancer therapy. <i>Biomarkers in Medicine</i> , 2017, 11, 53-67.	0.6	11
43	Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1â€”Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2535-2541.	0.8	383
44	High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy. <i>Oncotarget</i> , 2017, 8, 104430-104443.	0.8	5
45	Immuno-oncology combinations: raising the tail of the survival curve. <i>Cancer Biology and Medicine</i> , 2016, 13, 171-193.	1.4	98
46	ATIM-35. RESULTS OF THE PHASE IB KEYNOTE-028 MULTI-COHORT TRIAL OF PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH RECURRENT PD-L1-POSITIVE GLIOBLASTOMA MULTIFORME (GBM). <i>Neuro-Oncology</i> , 2016, 18, vi25-vi26.	0.6	40
47	A study of motivations and expectations of patients seen in phase 1 oncology clinics. <i>Cancer</i> , 2016, 122, 3501-3508.	2.0	24
48	Abstract CT323: Accelerated phase I trial of two schedules of the combination of the PARP inhibitor olaparib and AKT inhibitor AZD5363 using a novel inpatient dose escalation design in advanced cancer patients. <i>Cancer Research</i> , 2015, 75, CT323-CT323.	0.4	12
49	Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials. <i>Translational Oncogenomics</i> , 2015, Suppl. 1, 1-11.	1.7	19
50	CARD-Mediated Autoinhibition of cIAP1's E3 Ligase Activity Suppresses Cell Proliferation and Migration. <i>Molecular Cell</i> , 2011, 42, 569-583.	4.5	89
51	The Ripoptosome, a Signaling Platform that Assembles in Response to Genotoxic Stress and Loss of IAPs. <i>Molecular Cell</i> , 2011, 43, 432-448.	4.5	714
52	To fight or die â€” inhibitor of apoptosis proteins at the crossroad of innate immunity and death. <i>Current Opinion in Cell Biology</i> , 2010, 22, 872-881.	2.6	65
53	Regression of melanoma metastases following treatment with the n-bisphosphonate zoledronate and localised radiotherapy. <i>Clinical Immunology</i> , 2009, 131, 367-373.	1.4	29
54	The context and potential of epigenetics in oncology. <i>British Journal of Cancer</i> , 2009, 100, 571-577.	2.9	98

#	ARTICLE	IF	CITATIONS
55	Palliative treatments for patients with inoperable gastroesophageal cancers. International Journal of Palliative Nursing, 2006, 12, 306-317.	0.2	3
56	Semaphorin 3A Elicits Stage-Dependent Collapse, Turning, and Branching in <i>Xenopus</i> Retinal Growth Cones. Journal of Neuroscience, 2001, 21, 8538-8547.	1.7	187